| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.BMC.2010.09.050 |
| P698 | PubMed publication ID | 20947359 |
| P2093 | author name string | Po-Huang Liang | |
| R Ramajayam | |||
| Kian-Pin Tan | |||
| Hun-Ge Liu | |||
| P2860 | cites work | Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs | Q27641252 |
| The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor | Q27642450 | ||
| Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors | Q27648126 | ||
| Development of Broad-Spectrum Halomethyl Ketone Inhibitors Against Coronavirus Main Protease 3CLpro | Q27651072 | ||
| Structural Basis of Inhibition Specificities of 3C and 3C-like Proteases by Zinc-coordinating and Peptidomimetic Compounds | Q27653428 | ||
| Coronavirus as a possible cause of severe acute respiratory syndrome | Q28200848 | ||
| Characterization of a novel coronavirus associated with severe acute respiratory syndrome | Q28202401 | ||
| A novel coronavirus associated with severe acute respiratory syndrome | Q29617553 | ||
| Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. | Q30448643 | ||
| Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV. | Q33206632 | ||
| Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease | Q33217732 | ||
| Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro | Q33788800 | ||
| New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors | Q35620215 | ||
| Small molecules targeting severe acute respiratory syndrome human coronavirus | Q35970698 | ||
| Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents. | Q39967863 | ||
| Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease | Q43056416 | ||
| Myocardial protection of MCI-186 in rabbit ischemia-reperfusion. | Q44127913 | ||
| Virtual screening of novel noncovalent inhibitors for SARS-CoV 3C-like proteinase. | Q44843229 | ||
| Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. | Q44861300 | ||
| Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate | Q44899503 | ||
| High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase | Q45110672 | ||
| Polyprotein cleavage mechanism of SARS CoV Mpro and chemical modification of the octapeptide | Q45121648 | ||
| Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro | Q45164294 | ||
| Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors | Q46338365 | ||
| Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors | Q46493211 | ||
| Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters | Q46580414 | ||
| Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors | Q46775721 | ||
| A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods | Q46775741 | ||
| Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. | Q47924234 | ||
| Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. | Q48162562 | ||
| Effects of a novel free radical scavenger, MCl-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. | Q48719184 | ||
| Stable Benzotriazole Esters as Mechanism-Based Inactivators of the Severe Acute Respiratory Syndrome 3CL Protease | Q58239652 | ||
| Discovering severe acute respiratory syndrome coronavirus 3CL protease inhibitors: virtual screening, surface plasmon resonance, and fluorescence resonance energy transfer assays | Q79340566 | ||
| Development of potent inhibitors of the coxsackievirus 3C protease | Q80279253 | ||
| Structure-based design and synthesis of highly potent SARS-CoV 3CL protease inhibitors | Q80849382 | ||
| A pyrimidine-pyrazolone nucleoside chimera with potent in vitro anti-orthopoxvirus activity | Q83126753 | ||
| Individual and common inhibitors of coronavirus and picornavirus main proteases | Q83232837 | ||
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Coronaviridae | Q1134583 |
| SARSr-CoV | Q278567 | ||
| SARS-CoV-1 | Q85438966 | ||
| P304 | page(s) | 7849-7854 | |
| P577 | publication date | 2010-09-25 | |
| P1433 | published in | Bioorganic & Medicinal Chemistry | Q2904200 |
| P1476 | title | Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors | |
| P478 | volume | 18 |
| Q42084353 | 1,3-Diphenyl-4,5-dihydro-1H-pyrazol-5-one |
| Q35923992 | An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. |
| Q34332580 | Antiviral drugs specific for coronaviruses in preclinical development |
| Q35645639 | Benserazide, the first allosteric inhibitor of Coxsackievirus B3 3C protease |
| Q35488987 | Broad-spectrum inhibitors against 3C-like proteases of feline coronaviruses and feline caliciviruses. |
| Q95630795 | Chemistry and Biology of SARS-CoV-2 |
| Q46223071 | Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: structure-activity relationship study |
| Q38720941 | Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study |
| Q93180376 | Drug Development and Medicinal Chemistry Efforts Toward SARS-Coronavirus and Covid-19 Therapeutics |
| Q51781897 | Efficient one-pot synthesis of novel and diverse tetrahydroquinolines bearing pyranopyrazoles using organocatalyzed domino Knoevenagel/hetero Diels-Alder reactions. |
| Q27697642 | Fused-ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CL protease inhibitors |
| Q99571174 | Identification of potential inhibitors of SARS-CoV-2 main protease and spike receptor from 10 important spices through structure-based virtual screening and molecular dynamic study |
| Q40653601 | Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors. |
| Q43280688 | Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies |
| Q34218166 | Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery |
| Q57585721 | Selective cross-dehydrogenative C–O coupling of N-hydroxy compounds with pyrazolones. Introduction of the diacetyliminoxyl radical into the practice of organic synthesis |
| Q41120630 | Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an aza-decaline scaffold. |
| Q92097576 | Synthesis and Biological Evaluation of Quinolinone Compounds as SARS CoV 3CLpro Inhibitors |
| Q59009020 | Synthesis and Microbial Activity of Novel 3-Methyl-2-pyrazolin-5-one Derivatives |
| Q42250412 | Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors |
| Q98563452 | The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020 |
Search more.